Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good.
access to new medicine
Developing and testing new drugs costs a lot of money.
Nobel laureate Paul Romer’s key new insight was that human capital can produce ideas.
Profit incentivizes innovation and helps fund research and development.
Delay or denial of access to life-saving drugs is a potential death sentence.
Innovative new medicines can have a profound impact on the health and wellbeing of those stricken with illness. Unfortunately, Canadians are often denied these benefits for months, if not years, while they wait for their government to approve drugs already deemed safe and effective by regulators in the European Union and United States. Smarter regulation could save resources, reduce patient suffering, and improve the lives of Canadians.